Welcome to our dedicated page for Ekso Bionics SEC filings (Ticker: EKSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) files a range of reports and disclosure documents with the U.S. Securities and Exchange Commission that provide detailed insight into its exoskeleton and rehabilitation technology business. As a Nevada corporation listed on the Nasdaq Capital Market, the company submits annual and quarterly reports, current reports on Form 8-K, registration statements, and other filings under Commission File Number 001-37854.
Through its SEC filings, Ekso Bionics reports financial results, balance sheet details, and segment information related to its Enterprise Health and Personal Health activities. Earnings-related 8-K filings furnish press releases that discuss revenue, gross margin, operating expenses, and net loss, along with commentary on factors such as product mix between Enterprise Health and Personal Health devices and service margins. Investors can also review disclosures about cash balances, debt arrangements, and stockholders’ equity.
Current reports on Form 8-K document material events, including registered direct offerings of common stock, secured promissory note and security agreements, reverse stock split actions, and equity awards or severance arrangements for certain executives. For example, the company has filed 8-Ks describing a registered direct offering under an effective Form S-3 shelf registration statement, the terms of a secured term loan used for working capital and general corporate purposes, and the implementation and effective date of a reverse stock split intended to support compliance with Nasdaq’s minimum bid price requirements.
Other 8-K filings outline equity incentive awards, phantom performance-based restricted stock units, and change in control and severance agreements for key executives, including conditions for vesting and severance benefits. These documents provide detail on how Ekso Bionics structures compensation and protections around potential change in control events.
On this SEC filings page, users can access Ekso Bionics’ real-time submissions from the EDGAR system, including Forms 10-K and 10-Q for comprehensive financial and risk factor disclosures, as well as Form 4 and related insider transaction reports when available. AI-powered summaries help explain lengthy filings, highlight key terms in financing and equity agreements, and clarify the implications of capital markets transactions, reverse stock splits, and executive compensation arrangements for EKSO shareholders.
Ekso Bionics Holdings Chief Operating Officer Jason C. Jones increased his ownership through a small share acquisition tied to the company’s retirement plan. He acquired 1,308 shares of common stock on March 16, 2026 at $11.85 per share in an open-market purchase recorded under his 401(k) account, as part of the issuer’s 401(k) contribution matching program.
After this transaction, he indirectly holds 4,449 shares through the 401(k) and directly holds 25,621 shares of common stock. The share amounts disclosed have been adjusted to reflect a prior 1-for-15 reverse stock split.
Ekso Bionics Holdings, Inc. Chief Financial Officer Jerome Wong reported an open-market purchase of common stock through a 401(k) plan. He acquired 1,308 shares on March 16, 2026 at $11.85 per share, held indirectly via a 401(k) account under the company’s matching contribution program.
Following this transaction, he indirectly held 4,184 shares through the 401(k) and directly held 24,771 shares of common stock. A prior 1-for-15 reverse stock split effective on June 2, 2025 is reflected in the reported share amounts.
Ekso Bionics Holdings, Inc. announced that holders of approximately 50.4% of its voting stock approved, by written consent, a business combination under which Applied Digital affiliates will contribute Applied Digital Cloud Corporation ("Cloud") to Ekso in exchange for 138,216,820 newly issued shares of Common Stock.
The transaction contemplates an immediate $15.0M private subscription by Applied Parent, an amendment increasing authorized Common Stock to 290,000,000 shares, and a name change to ChronoScale Corporation. Post-Closing ownership is expected to be roughly 96% Contributor, 1% Applied Parent and 3% legacy Ekso holders (based on shares outstanding as of February 20, 2026), subject to closing conditions, Nasdaq approval, and other customary requirements.
Ekso Bionics Holdings, Inc. Schedule 13G filing discloses that Cedar Holdings Mgmt LLC beneficially owns 210,000 shares of Common Stock, representing 5.89% of the class based on February 20, 2026 outstanding shares of 3,563,381. The filing states Cedar has shared voting and dispositive power over the shares and that Keith Kosow may be deemed to beneficially own those shares by virtue of his role; Mr. Kosow does not directly own the Shares. The ownership percentages are tied to the issuer's Form 10-K disclosure of shares outstanding as of February 20, 2026.
Ekso Bionics Holdings, Inc. files its annual report describing a medical exoskeleton and rehabilitation technology business focused on Enterprise Health and Personal Health markets. The company details its product portfolio, CMS-backed reimbursement for the Ekso Indego Personal device, extensive regulatory requirements, and a sizable global patent estate.
A proposed business combination would contribute Applied Digital’s cloud computing subsidiary in exchange for 138,216,820 new Ekso shares, leaving Applied’s affiliate with roughly 97% of the combined company before other related issuances. The filing warns that if this transaction fails, Ekso expects limited liquidity, potential need for highly dilutive financing, and possible restructuring or wind-down.
Ekso Bionics Holdings, Inc. insider Daniel Asher, a more than ten percent owner, reported an indirect open-market purchase of common stock. On February 19, 2026, DBA Trading, LLC, an entity beneficially owned by Asher, bought 15,540 shares of common stock at an average price of $12.3013 per share. After this trade, DBA Trading, LLC held 270,432 common shares indirectly for Asher. Asher is also shown as indirectly holding 355,961 shares of convertible preferred stock through the Daniel Asher Descendants Trust, and directly holding 165,000 common shares, reflecting a significant overall stake in Ekso Bionics.
Ekso Bionics Holdings, Inc. insider Daniel Asher filed an amended Form 3 updating his beneficial ownership. The filing reports 355,961 shares of Convertible Preferred held indirectly through the Daniel Asher Descendants Trust, 151,663 shares of common stock held indirectly by DBA Trading, LLC, and 165,000 common shares held directly. A footnote clarifies that the DBA Trading, LLC common share balance was corrected from 156,763 to 151,663, and that Asher is deemed to control voting and dispositive power for both the trust and LLC holdings.
Ekso Bionics Holdings insider activity centers on an indirect open-market purchase and updated holdings. An entity associated with major shareholder Daniel Asher, DBA Trading, LLC, bought 1,200 shares of common stock at $9.60 per share, increasing its indirect position to 259,992 common shares. Asher is described as the beneficial owner of DBA Trading, LLC with voting and dispositive control over these shares.
The filing also reports indirect holdings of 355,961 shares of convertible preferred stock through the Daniel Asher Descendants Trust, where Asher is grantor and controls voting and dispositive power, and 165,000 common shares held directly. The preferred and direct common entries are reported as holdings rather than new transactions.
Ekso Bionics Holdings, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 291,146 shares of common stock, representing 9.99% of the class as of 12/31/2025. The filing is an Amendment No. 4 to a Schedule 13G/A and states shared voting and dispositive power over these shares.
The disclosure explains Armistice Capital acts as investment manager to the Armistice Capital Master Fund Ltd., the direct holder; Mr. Boyd is the managing member of Armistice Capital. The Master Fund is identified as having the right to receive dividends or sale proceeds.
Ekso Bionics Holdings, Inc. major shareholder Daniel Asher reported a series of indirect open-market purchases of common stock through DBA Trading, LLC between February 6 and February 13, 2026, at prices around the high-$8 to mid-$9 range per share.
Following these trades, DBA Trading, LLC held 258,792 shares of Ekso Bionics common stock indirectly for Asher, while he also reported 165,000 shares of common stock held directly. In addition, a trust for which Asher is grantor held 2,926 shares of convertible preferred stock, convertible into 355,960 shares of common stock, all reported as indirect beneficial ownership.